Market Overview

UPDATE: Oppenheimer Downgrades Emerson to Perform on Lack of Catalysts to Growth

Related EMR
Regal-Beloit Up 10% Following Power Transmission Purchase From Emerson Electric
US Stock Futures Up Ahead Of Economic Data

Oppenheimer reduced its rating on Emerson (NYSE: EMR) from Outperform to Perform and lowered its price target from $57 to $53.

Oppenheimer commented, "We are downgrading shares of EMR to Perform from Outperform, based on lack of high conviction catalysts to drive multiple expansion, and nearterm risk associated with exposure to capital spending. Initial guidance outlook for msd-hsd EPS growth appears a potentially more opportunistic backdrop for expectations, but does include a combined 17c headwind from pension and overlapping stock compensation plans (partially offset by ~6c favorable from lower restructuring spend, and material restructuring benefits)."

Emerson closed at $48.36 on Monday.

Latest Ratings for EMR

DateFirmActionFromTo
Dec 2014Deutsche BankDowngradesBuyHold
Dec 2014Bank of AmericaMaintainsNeutral
Nov 2014RBC CapitalInitiates Coverage onSector Perform

View More Analyst Ratings for EMR
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (EMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters